{
  "id": "5c6dfba77c78d69471000046",
  "type": "summary",
  "question": "Describe the mechanism of action of apalutamide.",
  "ideal_answer": "Apalutamide is a second-generation antiandrogen that inhibits the binding of androgen to androgen receptor (AR), nuclear translocation of the androgen-AR complex, and binding of AR transcription complex to DNA-binding sites and transcription elements. It does not show antagonist-to-agonist switch like bicalutamide. It is emerging as additional new option to treat castration-resistant prostate cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28636139",
    "http://www.ncbi.nlm.nih.gov/pubmed/29381490",
    "http://www.ncbi.nlm.nih.gov/pubmed/30426794",
    "http://www.ncbi.nlm.nih.gov/pubmed/29606109",
    "http://www.ncbi.nlm.nih.gov/pubmed/29420164",
    "http://www.ncbi.nlm.nih.gov/pubmed/29856649",
    "http://www.ncbi.nlm.nih.gov/pubmed/29695920",
    "http://www.ncbi.nlm.nih.gov/pubmed/29734647",
    "http://www.ncbi.nlm.nih.gov/pubmed/29626324",
    "http://www.ncbi.nlm.nih.gov/pubmed/27160947"
  ],
  "snippets": [
    {
      "text": "Second-generation NSAA receptor antagonists (enzalutamide, apalutamide and darolutamide) are emerging as additional new options to treat castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29420164",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide (ARN-509), a second-generation androgen receptor antagonist, recently received approval in the nonmetastatic (M0) CRPC space. Similar to enzalutamide, apalutamide inhibits the binding of androgen to androgen receptor (AR), nuclear translocation of the androgen-AR complex, and binding of AR transcription complex to DNA-binding sites and transcription elements. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29695920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29626324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ongoing clinical trials for different subgroups of prostate cancer patients include the evaluation of the second-generation AR antagonists enzalutamide, apalutamide and darolutamide, of inhibitors of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, of inhibitors of DNA damage response, of targeted alpha therapy and of prostate-specific membrane antigen (PSMA) targeting approaches. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29734647",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " One of these agents is apalutamide, which seems to be a promising AR antagonist for the treatment of CRPC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29856649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Apalutamide is an oral, investigational, AR antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29856649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27160947",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND\nApalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27160947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nApalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29420164",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similar to enzalutamide, apalutamide inhibits the binding of androgen to androgen receptor (AR), nuclear translocation of the androgen-AR complex, and binding of AR transcription complex to DNA-binding sites and transcription elements.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29695920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide (ARN-509), a second-generation androgen receptor antagonist, recently received approval in the nonmetastatic (M0) CRPC space.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29695920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29626324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Apalutamide is an oral, investigational, AR antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29856649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide, an androgen receptor inhibitor, has substantial clinical response in nonmetastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30426794",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27160947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29420164",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}